Repare Therapeutics Statistics
Total Valuation
RPTX has a market cap or net worth of $61.76 million. The enterprise value is -$60.66 million.
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RPTX has 42.89 million shares outstanding. The number of shares has increased by 0.85% in one year.
| Current Share Class | 42.89M |
| Shares Outstanding | 42.89M |
| Shares Change (YoY) | +0.85% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 1.16% |
| Owned by Institutions (%) | 32.56% |
| Float | 22.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 57.43 |
| Forward PS | 8.13 |
| PB Ratio | 0.50 |
| P/TBV Ratio | 0.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.42, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.42 |
| Quick Ratio | 7.18 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -71.64% and return on invested capital (ROIC) is -45.29%.
| Return on Equity (ROE) | -71.64% |
| Return on Assets (ROA) | -40.19% |
| Return on Invested Capital (ROIC) | -45.29% |
| Return on Capital Employed (ROCE) | -104.62% |
| Revenue Per Employee | $8,318 |
| Profits Per Employee | -$991,426 |
| Employee Count | 129 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RPTX has paid $1.18 million in taxes.
| Income Tax | 1.18M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.84% in the last 52 weeks. The beta is 0.84, so RPTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -61.84% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 2.04 |
| Relative Strength Index (RSI) | 59.25 |
| Average Volume (20 Days) | 116,548 |
Short Selling Information
The latest short interest is 562,114, so 1.31% of the outstanding shares have been sold short.
| Short Interest | 562,114 |
| Short Previous Month | 555,076 |
| Short % of Shares Out | 1.31% |
| Short % of Float | 2.48% |
| Short Ratio (days to cover) | 2.68 |
Income Statement
In the last 12 months, RPTX had revenue of $1.07 million and -$127.89 million in losses. Loss per share was -$3.01.
| Revenue | 1.07M |
| Gross Profit | 395,000 |
| Operating Income | -130.88M |
| Pretax Income | -83.68M |
| Net Income | -127.89M |
| EBITDA | -128.28M |
| EBIT | -130.88M |
| Loss Per Share | -$3.01 |
Full Income StatementBalance Sheet
The company has $124.23 million in cash and $1.37 million in debt, giving a net cash position of $122.86 million or $2.86 per share.
| Cash & Cash Equivalents | 124.23M |
| Total Debt | 1.37M |
| Net Cash | 122.86M |
| Net Cash Per Share | $2.86 |
| Equity (Book Value) | 125.10M |
| Book Value Per Share | 2.92 |
| Working Capital | 121.42M |
Full Balance SheetCash Flow
| Operating Cash Flow | -117.51M |
| Capital Expenditures | n/a |
| Free Cash Flow | -117.51M |
| FCF Per Share | -$2.74 |
Full Cash Flow StatementMargins
| Gross Margin | 36.81% |
| Operating Margin | -12,197.76% |
| Pretax Margin | -11,809.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.85% |
| Shareholder Yield | -0.85% |
| Earnings Yield | -205.64% |
| FCF Yield | -188.95% |
Analyst Forecast
The average price target for RPTX is $4.50, which is 212.50% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.50 |
| Price Target Difference | 212.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RPTX has an Altman Z-Score of -2.59 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.59 |
| Piotroski F-Score | 1 |